Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

Linda Stein Gold, April W. Armstrong, Robert Bissonnette, Nina Magnolo, Ronald Vender, Michael Sebastian, María Laura Galimberti, Athanasios Tsianakas, Marcelo Arnone, Paul Wallace, Margrit Simon, Josep Riera‐Monroig, Sascha Gerdes, Jill Waibel, Álvaro González‐Cantero, Beate Schwarz, Yayoi Tada, Michael Cecchini, Benjamin D. Ehst, Leon Kircik, Lea Kephart, Ofelia Reyes-Servin, Bassey Edem, Jennifer H Campbell, Yaung‐Kaung Shen, Kellen G. Cresswell, Shu Li, Cynthia Marie Carver DeKlotz, Fabio P. Nunes, Kim Papp

2025The Lancet18 citationsDOI Open Access PDF

Topics & Concepts

Plaque psoriasisMedicinePlaceboInternal medicineClinical trialPsoriasisGastroenterologyOral cavityDermatologyOral administrationPhase (matter)Adverse effectMEDLINEPhases of clinical researchDental plaquePlacebo responsePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin Diseases

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 &amp; 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials

Topics & Concepts

Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials